ARCHIVES

FDA Approves Gleevec For First Line Rx Of CML

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Darbepoetin Didn’t Decrease Blood Transfusions, Lowered Overall Survival, Study Finds

April 27, 2007

Herceptin With Adjuvant Chemo Improves Disease-Free Survival, Phase III Trial Finds

January 29, 2010

“Our Job Is to Be The One Agency That Speaks To Cancer”

October 28, 1994

Low Percentage Of Trials Published In Medical Journals

October 31, 2008

C. Gordon Zubrod, 84, Dies, Led Chemotherapy Research, Built Cooperative Group System

January 29, 1999

Radium-233 Dichloride Increased Overall Survival in Phase III Trial

June 29, 2012